Monographie - Tigecycline - Stabilis 4.0

Ultimo aggiornamento :
19/11/2024

Antibiotico

Tigecycline

Iniezione

Stabilità in soluzione

Stabilità in miscela

Fattori che influenzano la stabilità

Compatibilità

metodo di iniezione

Bibliografia

pdf

Struttura chimica

Nome commerciale

Nome commerciale

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Eticina	Messico
Grexyl	Messico
Linicetil	Messico
Mrsacin	Turchia
Tecygen	Chile
Tigecid	Turchia
Tigecilina	Argentina, Chile, Ecuador
Tigecycline	Canada
Tigetop	Chile
Tizoxim	Argentina
Tygacil	Arabia Saudita, Argentina, Austria, Belgio, Canada, Chile, Colombia, Danimarca, Ecuador, Emirati Arabi Uniti, Finlandia, Francia, Germania, Giappone, Gran Bretagna, Grecia, Irlanda, Islanda, Italia, Lussemburgo, Malaysia, Messico, Norvegia, nuova Zelanda, Paesi Bassi, Perù, Polonia, Portogallo, Romania, Spagna, Stati Uniti d’America, Svezia, Svizzera, Turchia, Ungheria, Venezuela
Zomiprerin	Perù

Bibliografia

Iniezione

Bibliografia : Tigecycline

	tipo	pubblicazione
2262	Rivista	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3128	Laboratorio	Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013
3254	Rivista	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3332	Laboratorio	Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012
3531	Laboratorio	Morphine sulphate 10 mg/mL injection BP – Summary of Product Characteristics Wockhardt 2014
3644	Laboratorio	Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010
3674	Laboratorio	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3887	Rivista	Robiyanto R, Zaidi S.T.R, . Shastri M.D, Castelino R.L, Wanandy S.T, Jose M.D, . Patel R.P. Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Perit Dial Int 2016 ; 36:410-414.
4055	Rivista	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Rivista	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4528	Rivista	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	Rivista	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales